Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia
NCT03904251 · Jonsson Comprehensive Cancer Center · PHASE1 · terminated · last registry update 2023-11-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “slow accrual” | – | Registry record, Jonsson Comprehensive Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD33 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-04-18Results posted on the registry: Robert Redner, MD, mitoxantrone + etoposide + gemtuzumab ozogamicin (NCT03839446)
- 2023-08-16Phase 3 first posted: Princess Maxima Center for Pediatric Oncology, Standard Intervention Rc + Investigational Intervention Rc (NCT05994690)
- 2023-07-20Also stopped (withdrawn): Actinium Pharmaceuticals, Lintuzumab-Ac225 + Venetoclax (NCT03932318)
- 2023-05-24Results posted on the registry: M.D. Anderson Cancer Center, Anti-OX40 Agonist Monoclonal Antibody PF-04518600 + Avelumab (NCT03390296)
- 2023-03-10Also stopped (terminated): Weill Medical College of Cornell University, CPX-351 + Gemtuzumab Ozogamicin (NCT03878927)
- 2023-02-02Also stopped (withdrawn): Rush University Medical Center, amifostine trihydrate + cytarabine (NCT00003407)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision